Antiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agents (Q38101275)

28 August 2017

title

Antiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agents (English)

1 reference

28 August 2017

1 reference

1 reference

1

Dominick J Angiolillo

1 reference

28 August 2017

José Luis Ferreiro

2

1 reference

28 August 2017

publication date

1 August 2013

1 reference

American journal of cardiovascular drugs

28 August 2017

published in

1 reference

28 August 2017

volume

13

1 reference

28 August 2017

issue

4

1 reference

28 August 2017

page(s)

233-250

1 reference

Heart disease and stroke statistics--2011 update: a report from the American Heart Association

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

The P2Y12 receptor as a therapeutic target in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Platelet activation and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Central role of the P2Y12 receptor in platelet activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

21 January 2018

New anticoagulant drugs

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Cell adhesion mechanisms in platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Platelet receptors and signaling in the dynamics of thrombus formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Activation of platelet function through G protein-coupled receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

New directions in antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Thrombin and platelet activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Blood coagulation: hemostasis and thrombin regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

New antithrombotic agents: are they needed and what can they offer to patients with a non-ST-elevation acute coronary syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Protease-activated receptors in hemostasis, thrombosis and vascular biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Anti-glycoprotein VI treatment severely compromises hemostasis in mice with reduced alpha2beta1 levels or concomitant aspirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Adverse impact of bleeding on prognosis in patients with acute coronary syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Basic principles of platelet biology and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Advances in antiplatelet therapy: agents in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Genetic determinants of response to clopidogrel and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in plat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Clopidogrel with or without omeprazole in coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Elinogrel: pharmacological principles, preclinical and early phase clinical testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percuta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOV

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patie

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Update on the clinical development of cangrelor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Platelet inhibition with cangrelor in patients undergoing PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Intravenous platelet blockade with cangrelor during PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Platelet thrombin receptor antagonism and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Risk of intracranial hemorrhage with protease-activated receptor-1 antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Vorapaxar in the secondary prevention of atherothrombotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Atopaxar: a review of its mechanism of action and role in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

One-year cardiovascular event rates in outpatients with atherothrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Apixaban with antiplatelet therapy after acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Rivaroxaban in patients with a recent acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Comparison of fondaparinux and enoxaparin in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Clinical Events as a Function of Proton Pump Inhibitor Use, Clopidogrel Use, and Cytochrome P450 2C19 Genotype in a Large Nationwide Cohort of Acute Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non–ST-segment elevation myocardial infarction: The TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Design and rationale of the Treatment of Acute Coronary Syndromes with Otamixaban trial: A double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non–ST-segment elevation acute coronary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40256-013-0022-7

10.1007/S40256-013-0022-7

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1043842117

0 references

1 reference